Peptron Inc (087010.KQ) stock: key figures, P/E, revenue and dividend
Health Care · Biotechnology · South Korea · ISIN KR7087010005
Peptron Inc financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 3.15 bn KRW | 5.63 bn KRW |
| Gross profit | 1.11 bn KRW | 1.53 bn KRW |
| Operating income | -16.54 bn KRW | -21.26 bn KRW |
| EBIT | -21.15 bn KRW | -13.01 bn KRW |
| Net income | -22.03 bn KRW | -13.82 bn KRW |
| Diluted EPS – continuing operations | -948.77 KRW | -594.74 KRW |
Full history since 2014, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Peptron Inc
Peptron, Inc. engages in the development of peptide-based medicines. The company's technologies include long acting; and SmartDepot, an ultrasonic spray drying technology for the preparation of sustained release injectable microsphere formulation of drug. Its research and development products include Luphere Depot for prostate cancer, endometriosis, uterine fibroids, premenopausal breast cancer, and puberty; SR-Octreotide for the treatment of acromegaly; SR-Exenatide to treat type 2 diabetes; and SR-Exenatide (PT320) for Parkinson's and Alzheimer's disease. Peptron, Inc. was founded in 1997 and is headquartered in Daejeon, South Korea.
More stocks
- Fujian Snowman Co Ltd (002639.SZ)
- HIAG Immobilien Holding AG (HIAG.SW)
- Trump Media & Technology Group Corp. (DJT)
- Kuaijishan Shaoxing Rice Wine (601579.SS)
- Shinkong Insurance Co Ltd (2850.TW)
- OCULAR THERAPEUTIX, INC (OCUL)
- Dom Development SA (DOM.WA)
- Changzhou Fusion New Material Co. Ltd. A (688503.SS)
- Northking Information Technology Co (002987.SZ)
- Ryerson Holding Corp (RYZ)
- PharmaBlock Sciences Nanjing Inc Class A (300725.SZ)
- Neinor Homes SA (HOME.MC)
Not investment advice. All data without warranty, price as of 30.10.2026. Details in the risk notice.